Tracks how long adults with rheumatoid arthritis stay on newer arthritis drugs
Follows adults with rheumatoid arthritis taking targeted or biologic drugs over time.
Plain-language title generated from the registry record
Registry title: Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.
Key facts
- Where
- Seville, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with rheumatoid arthritis who have already received at least one dose of the study drugs and are followed at one rheumatology clinic.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Adult rheumatoid arthritis, diagnosed by the 2010 ACR / EULAR criteria
- Earlier treatment
- Must have received at least one dose of the study drugs (targeted synthetic or biologic disease-modifying drugs)
Main reasons for not taking part
- Medical records lack enough starting and final data for the analysis
- More than 50% of the data to be collected are missing
- Fewer than two complete clinical evaluations (baseline and final)
Read by machine on 12 November 2026.
Where in Spain
- Hospital Universitario Virgen MacarenaSeville, SpainContact: Blanca Estela Hernández CruzTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Trial code
- NCT05062421
- Record updated
- 17 November 2021
- Original description
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).Read full original descriptionShow less
Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).
These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
Inclusion: Patients aged ≥18 years; With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria; Who have received at least one of the doses of the study drugs; In follow-up in the consultations of the UGC of Rheumatology of the HUVM; With at least two complete evaluations (baseline and final) of clinical variables.
Exclusion: Patients where the medical records lack sufficient baseline and final variables to perform the analysis; Patients in whom more than 50% of the variables to be collected are missing in the data collection.